Medical Condition News

RSS

Researchers identify genes that influence degeneration of the hippocampus

In a genome-wide association (GWA) study, researchers from Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) have identified several genes which influence degeneration of the hippocampus, the part of the brain most associated with Alzheimer disease (AD).

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients

A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don’t respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.

29 Jun 2012

Novo Nordisk, BRI collaborate to speed-up translational research of autoimmune diseases

Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, Wash., and Novo Nordisk, a global health care company headquartered in Denmark, today announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.

29 Jun 2012

Sinai Hospital begins to use Solitaire FR device for treatment of acute stroke

Sinai Hospital has begun use of a new device that provides timely live-saving treatment for acute stroke patients. The Solitaire FR revascularization device is designed to minimize damage caused by blockage of an artery to the brain by mechanically removing blood clots and restoring blood flow.

29 Jun 2012

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.

29 Jun 2012

Scientists use patient cells to generate human model of Huntington's

Scientists at the Gladstone Institutes and an international team of researchers have generated a human model of Huntington's disease-directly from the skin cells of patients with the disease.

29 Jun 2012

Medifast to open first Rochester Weight Loss Center in July 2012

Medifast, the fast-growing weight loss system in Minnesota, is pleased to announce the opening of its first Rochester, MN Weight Loss Center in July 2012. The newest Medifast Weight Control Center will be conveniently located at 2048 Superior Dr NW, Suite 300 Rochester, MN 55901

29 Jun 2012

Scientists use new method to assemble massive catalogue of data on proteins

Scientists at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen have used a new method to assemble a massive catalogue of data on proteins. This gives them unprecedented insight into a process called protein phosphorylation.

29 Jun 2012

New laboratory model for Huntington's disease

Cedars-Sinai scientists have joined with expert colleagues around the globe in using stem cells to develop a laboratory model for Huntington's disease, allowing researchers for the first time to test directly on human cells potential treatments for this fatal, inherited disorder.

29 Jun 2012

DFG to set up new CRC/Transregio that focuses on multiple sclerosis research

On July 1, 2012, the German Research Foundation (DFG) will set up a new Transregional Collaborative Research Center (CRC/Transregio) to be coordinated by the University Medical Center of Johannes Gutenberg University Mainz.

29 Jun 2012

Benefits of complementary and alternative medicine for back pain

Got a pain in the neck or back? Relief could be just an adjustment away. In a recent study, "Perceived Benefit of Complementary and Alternative Medicine (CAM) for Back Pain" (Journal of the American Board of Family Medicine, May - June 2010, Vol. 23 No.3), the majority of respondents receiving CAM for back pain reported significant benefits from the various treatments.

29 Jun 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Senior citizens report fewer visual impairment problems than their counterparts

Today's senior citizens are reporting fewer visual impairment problems than their counterparts from a generation ago, according to a new Northwestern Medicine study. Improved techniques for cataract surgery and a reduction in the prevalence of macular degeneration may be the driving forces behind this change, the researchers said.

29 Jun 2012

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Researchers create first animal model for RA

Researchers at Northwestern University Feinberg School of Medicine have created the first animal model that spontaneously develops rheumatoid arthritis (RA) and is predisposed towards atherosclerosis, or hardening of the arteries.

29 Jun 2012

Social interactions during adolescence can affect health many years into adulthood

Social interactions during adolescence can affect health many years into adulthood, according to research published in the open access journal PLoS ONE.

29 Jun 2012

FSS’ FlexStent Iliac system receives CE Mark

Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has extended its CE Mark authorized family of peripheral vascular stents to include the FlexStent Iliac Self Expanding Stent System.

29 Jun 2012

Researchers create 'Huntington's disease in a dish' to enable search for treatment

Johns Hopkins researchers, working with an international consortium, say they have generated stem cells from skin cells from a person with a severe, early-onset form of Huntington's disease (HD), and turned them into neurons that degenerate just like those affected by the fatal inherited disorder.

29 Jun 2012